Bayer Seeks Glyphosate Tariffs, Angering Farmers Who Backed Its Roundup Win

Bayer filed a petition with the U.S. Department of Commerce and International Trade Commission seeking import duties on Chinese-made glyphosate, the key ingredient in Roundup weedkiller. The move has infuriated farm groups that helped the German pharmaceutical giant win a Supreme Court ruling in late June that shielded the company from state-level cancer liability claims. A Texas A&M study found similar tariffs cost U.S. crop growers $6.9 billion from 2021 to 2025.

How farm groups backed Bayer, then got burned

Twelve agricultural organizations, led by the American Farm Bureau Federation, filed a friend-of-the-court brief supporting Bayer before the Supreme Court in late June. The group included the National Corn Growers Association, American Soybean Association, and National Association of Wheat Growers. They warned that a loss could jeopardize farmers’ access to glyphosate, which they described as central to modern weed control.

Bayer CEO Bill Anderson called the ruling a win that provides regulatory clarity for developing agricultural tools. Within weeks, Bayer turned around and filed the tariff petition, claiming Chinese dumping margins range from 69% to over 100%.

The cost to farmers of higher glyphosate prices

Farm groups say the tariff petition throws financially squeezed farmers under the bus. A Bayer spokesperson told Fortune the move was intended to protect farmers and support long-term U.S. production. But the Texas A&M study directly contradicts that claim: tariffs of the type Bayer is seeking already cost crop growers $6.9 billion from 2021 to 2025.

The National Corn Growers Association released a separate report showing U.S. farmers already pay substantially more for crop inputs than Brazilian competitors. Across all corn seed comparisons, U.S. prices averaged 68% higher than Brazil’s from 2023 to 2025. U.S. herbicide prices were often nearly double Brazil’s.

Why Bayer says tariffs are necessary

Bayer argues the domestic glyphosate business as it stands today is not sustainable. The company claims Chinese producers are dumping the ingredient in the U.S. market and selling below fair value. A Bayer spokesperson said the action is needed to support long-term U.S. production for American farmers.

However, farm groups dispute this framing. They argue that tariffs will simply raise their costs at a time when input prices already exceed those paid by international competitors. The petition is now under review by an independent body at the Department of Commerce and International Trade Commission.

Bayer stock up 84% but faces regulatory risk

Bayer stock has delivered an 83.8% return over the past 12 months. The company trades on a price-to-sales ratio of 1.1x, well below the pharmaceutical industry average of 2.6x and peer average of 3.2x, suggesting the shares remain undervalued on fundamentals. However, analysts note that ongoing disputes with U.S. farm groups over glyphosate tariffs highlight regulatory and relationship risks that may affect investor sentiment around the stock.

Final Thoughts

Bayer’s tariff petition has fractured its relationship with the farm groups that helped it win Supreme Court protection from Roundup lawsuits. With the stock up 84% but facing regulatory headwinds, investors should monitor whether the tariff decision damages the company’s credibility with its core agricultural customer base.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.